...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention

Nextblockbuster wrote "I wonder if this patent issuance was a catalyst for a pending upcoming deal?"

You could be right Nextblockbuster. My notes paraphrased from the Zenith December 2016 Annual Meeting:

Several patents, a dozen or more, at various stages of examination and issuance. Followed a new process in a US Fast track patent approach that was granted in March 2016. You break down patent into most important component and you put that through the fast track…... something finalized Q1 2017. The rest of it, the divisional patent the rest of patent will go normal process and this can take 3 years. Need published patent to get a licensing deal over the finish line in China. Once you have fast track approved, the follow on patents in subsequent other countries happen very fast.

 

Share
New Message
Please login to post a reply